Sesen Bio, Inc. - Common Stock [SESN]
$1.26 0.00 (0.00%)
Market Cap 110 Million
Sesen Bio Inc is a late-stage clinical company engaged in next-generation antibody-drug conjugate therapies for the treatment of cancer based on the company's Targeted Protein Therapeutics platform. The company's lead program, Vicinium, also known as VB4-845, is currently in a Phase 3 registration trial, the VISTA Trial, for the treatment of high-grade non-muscle invasive bladder cancer.
EPS -0.08 P/E Ratio 0.00
Previous Earnings Mon, Mar 4, 2019
Pay Date --
|Symbol||Price||Day %||YTD %|
This list of trending stocks may change throughout the trading day.